S-1/A: Know Labs Eyes $6 Million in Public Offering to Advance Non-Invasive Glucose Monitoring Technology

Know Labs aims to raise $6 million through a public offering of units to further develop and commercialize its non-invasive glucose monitoring technology.

Summary

• Know Labs is conducting a firm commitment public offering of 12,000,000 units, each comprising one share of common stock and one warrant to purchase one share of common stock, at an assumed offering price of $0.50 per unit.
• The offering aims to raise gross proceeds of approximately $6.0 million.
• The Public Warrants will have an exercise price of $0.50 per share and will be exercisable upon FDA clearance of the KnowU product or a change in control of the company, expiring five years from issuance.
• The company intends to use the net proceeds for continuing operating expenses and working capital.
• Boustead Securities, LLC is the sole book-running manager for the offering.
• The company has granted the underwriters an option to purchase an additional 1,800,000 units to cover over-allotments.
• The company is also registering the shares of common stock issuable from time to time upon exercise of the Public Warrants included in the units offered hereby.

Sentiment

Score: 6

Explanation: The document is mostly neutral, outlining the terms of a public offering. While the offering itself is a positive step for the company's financial position, the document also acknowledges the risks involved and the company's history of operating losses.

Positives

• The offering will provide Know Labs with additional capital to advance its non-invasive glucose monitoring technology.
• The warrants, if exercised, could provide additional capital to the company in the future.
• The company has the potential to disrupt the glucose monitoring market with its non-invasive technology.

Negatives

• The offering price may be at a discount to the current market price of the common stock.
• The warrants are only exercisable upon FDA clearance of the KnowU product or a change in control of the company, which may not occur.
• The company has a history of operating losses and may not achieve profitability.

Risks

• Investing in the company's securities involves a high degree of risk, as detailed in the Risk Factors section of the prospectus.
• The company may not be able to achieve FDA clearance of its KnowU product.
• The market price of the company's common stock may fluctuate.
• The company may not be able to maintain a listing of its common stock on the NYSE American.
• Future issuances of common stock could cause dilution to existing shareholders.

Future Outlook

The company plans to expand its sensor technology to other non-invasive medical diagnostic applications following FDA clearance of its non-invasive blood glucose monitoring device.

Industry Context

The company operates in the competitive medical device industry, specifically targeting the glucose monitoring market, and aims to disrupt the market with its non-invasive technology.

Comparison to Industry Standards

• The company's technology is compared to existing continuous glucose monitors from Abbott Labs (Freestyle Libre) and Dexcom (G6).
• The company aims to provide a non-invasive alternative to existing glucose monitoring solutions.
• The company's technology is differentiated from industry leaders as it completely non-invasively monitors blood glucose levels.

Stakeholder Impact

• Shareholders may experience dilution as a result of the public offering.
• The company's employees will benefit from the additional capital, which will support ongoing operations and product development.
• Customers may benefit from the development of a non-invasive glucose monitoring solution.
• The company's suppliers and creditors will benefit from the company's improved financial position.

Next Steps

• The company will work to complete the public offering.
• The company will continue to develop and test its KnowU product.
• The company will seek FDA clearance for its KnowU product.
• The company will explore potential avenues for moving its first product and potential follow-on products into the marketplace.

Key Dates

Keywords

glucose monitoring, public offering, Know Labs, warrants, FDA clearance, common stock, non-invasive, Boustead Securities, units, KNW